Carbohydrate 19-9 antigen is not a marker of liver disease in patients with cystic fibrosis

Nora Bettinardi, Irene Felicetta, Paolo A. Tomasi, Carla Colombo

Research output: Contribution to journalArticle

Abstract

Serum concentration of carbohydrate 19-9 antigen (CA 19-9), a sensitive marker of pancreatic cancer and cholangiocarcinoma, increases in a variety of liver diseases due to higher production and release by bile duct cells. Biliary epithelial cells are primarily affected in liver disease associated with cystic fibrosis (CF), which develops in up to 30% of CF patients. Our aim was to evaluate the usefulness of serum CA 19-9 concentration as a test of liver involvement in CF. Serum concentration of CA 19-9, liver enzymes, bile acids, and total amylase was determined in 107 CF patients (49 with and 58 without liver disease) and 56 healthy subjects. Serum CA 19-9 concentration was significantly higher in CF patients (67 U/ml, 95% Cl 53.5-80.5 U/ml) than in controls (11.8 U/ml, 95% Cl 2.5-44 U/ml; p <0.001) and in CF patients with liver disease (92.3 U/ml, 95% Cl 75-109.5 U/ml) compared to CF patients without liver disease (46.6 U/ml, 95% Cl 27.8-65.4 U/ml; p <0.001). In CF patients, stepwise logistic regression analysis identified alanine aminotransferase, γ-glutamyltranspeptidase, amylase, and CA 19-9 as the most useful predictors of liver disease (p <0.0001). Receiver-operating characteristic (ROC) curve analysis revealed γ-glutamyltranspeptidase and CA 19-9 as the best tests for identification of liver disease in CF patients; at a CA 19-9 cut-off arbitrarily fixed at 73 U/ml, positive and negative predictive value was 70% and 78%, respectively (sensitivity 57%, specificity 81%). To increase sensitivity to 94%, the cut-off had to be fixed at 31 U/ml, which corresponds to a specificity of only 36.2% (predictive value 33%). Our study indicates that measurement of the serum CA 19-9 concentration alone cannot be proposed as a reliable test of early hepatic involvement in CF.

Original languageEnglish
Pages (from-to)311-316
Number of pages6
JournalClinical Chemistry and Laboratory Medicine
Volume41
Issue number3
DOIs
Publication statusPublished - 2003

Fingerprint

Cystic Fibrosis
Liver
Liver Diseases
Carbohydrates
Antigens
Serum
Amylases
Cholangiocarcinoma
Bile Acids and Salts
Alanine Transaminase
Regression analysis
Ducts
Bile Ducts
Pancreatic Neoplasms
Logistics
ROC Curve
Healthy Volunteers
Logistic Models
Epithelial Cells
Regression Analysis

Keywords

  • CA 19-9
  • Cystic fibrosis
  • Liver disease

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Carbohydrate 19-9 antigen is not a marker of liver disease in patients with cystic fibrosis. / Bettinardi, Nora; Felicetta, Irene; Tomasi, Paolo A.; Colombo, Carla.

In: Clinical Chemistry and Laboratory Medicine, Vol. 41, No. 3, 2003, p. 311-316.

Research output: Contribution to journalArticle

Bettinardi, Nora ; Felicetta, Irene ; Tomasi, Paolo A. ; Colombo, Carla. / Carbohydrate 19-9 antigen is not a marker of liver disease in patients with cystic fibrosis. In: Clinical Chemistry and Laboratory Medicine. 2003 ; Vol. 41, No. 3. pp. 311-316.
@article{6c097525b4ba47dd8b0ae62e3c9a377a,
title = "Carbohydrate 19-9 antigen is not a marker of liver disease in patients with cystic fibrosis",
abstract = "Serum concentration of carbohydrate 19-9 antigen (CA 19-9), a sensitive marker of pancreatic cancer and cholangiocarcinoma, increases in a variety of liver diseases due to higher production and release by bile duct cells. Biliary epithelial cells are primarily affected in liver disease associated with cystic fibrosis (CF), which develops in up to 30{\%} of CF patients. Our aim was to evaluate the usefulness of serum CA 19-9 concentration as a test of liver involvement in CF. Serum concentration of CA 19-9, liver enzymes, bile acids, and total amylase was determined in 107 CF patients (49 with and 58 without liver disease) and 56 healthy subjects. Serum CA 19-9 concentration was significantly higher in CF patients (67 U/ml, 95{\%} Cl 53.5-80.5 U/ml) than in controls (11.8 U/ml, 95{\%} Cl 2.5-44 U/ml; p <0.001) and in CF patients with liver disease (92.3 U/ml, 95{\%} Cl 75-109.5 U/ml) compared to CF patients without liver disease (46.6 U/ml, 95{\%} Cl 27.8-65.4 U/ml; p <0.001). In CF patients, stepwise logistic regression analysis identified alanine aminotransferase, γ-glutamyltranspeptidase, amylase, and CA 19-9 as the most useful predictors of liver disease (p <0.0001). Receiver-operating characteristic (ROC) curve analysis revealed γ-glutamyltranspeptidase and CA 19-9 as the best tests for identification of liver disease in CF patients; at a CA 19-9 cut-off arbitrarily fixed at 73 U/ml, positive and negative predictive value was 70{\%} and 78{\%}, respectively (sensitivity 57{\%}, specificity 81{\%}). To increase sensitivity to 94{\%}, the cut-off had to be fixed at 31 U/ml, which corresponds to a specificity of only 36.2{\%} (predictive value 33{\%}). Our study indicates that measurement of the serum CA 19-9 concentration alone cannot be proposed as a reliable test of early hepatic involvement in CF.",
keywords = "CA 19-9, Cystic fibrosis, Liver disease",
author = "Nora Bettinardi and Irene Felicetta and Tomasi, {Paolo A.} and Carla Colombo",
year = "2003",
doi = "10.1515/CCLM.2003.050",
language = "English",
volume = "41",
pages = "311--316",
journal = "Clinical Chemistry and Laboratory Medicine",
issn = "1434-6621",
publisher = "Walter de Gruyter GmbH",
number = "3",

}

TY - JOUR

T1 - Carbohydrate 19-9 antigen is not a marker of liver disease in patients with cystic fibrosis

AU - Bettinardi, Nora

AU - Felicetta, Irene

AU - Tomasi, Paolo A.

AU - Colombo, Carla

PY - 2003

Y1 - 2003

N2 - Serum concentration of carbohydrate 19-9 antigen (CA 19-9), a sensitive marker of pancreatic cancer and cholangiocarcinoma, increases in a variety of liver diseases due to higher production and release by bile duct cells. Biliary epithelial cells are primarily affected in liver disease associated with cystic fibrosis (CF), which develops in up to 30% of CF patients. Our aim was to evaluate the usefulness of serum CA 19-9 concentration as a test of liver involvement in CF. Serum concentration of CA 19-9, liver enzymes, bile acids, and total amylase was determined in 107 CF patients (49 with and 58 without liver disease) and 56 healthy subjects. Serum CA 19-9 concentration was significantly higher in CF patients (67 U/ml, 95% Cl 53.5-80.5 U/ml) than in controls (11.8 U/ml, 95% Cl 2.5-44 U/ml; p <0.001) and in CF patients with liver disease (92.3 U/ml, 95% Cl 75-109.5 U/ml) compared to CF patients without liver disease (46.6 U/ml, 95% Cl 27.8-65.4 U/ml; p <0.001). In CF patients, stepwise logistic regression analysis identified alanine aminotransferase, γ-glutamyltranspeptidase, amylase, and CA 19-9 as the most useful predictors of liver disease (p <0.0001). Receiver-operating characteristic (ROC) curve analysis revealed γ-glutamyltranspeptidase and CA 19-9 as the best tests for identification of liver disease in CF patients; at a CA 19-9 cut-off arbitrarily fixed at 73 U/ml, positive and negative predictive value was 70% and 78%, respectively (sensitivity 57%, specificity 81%). To increase sensitivity to 94%, the cut-off had to be fixed at 31 U/ml, which corresponds to a specificity of only 36.2% (predictive value 33%). Our study indicates that measurement of the serum CA 19-9 concentration alone cannot be proposed as a reliable test of early hepatic involvement in CF.

AB - Serum concentration of carbohydrate 19-9 antigen (CA 19-9), a sensitive marker of pancreatic cancer and cholangiocarcinoma, increases in a variety of liver diseases due to higher production and release by bile duct cells. Biliary epithelial cells are primarily affected in liver disease associated with cystic fibrosis (CF), which develops in up to 30% of CF patients. Our aim was to evaluate the usefulness of serum CA 19-9 concentration as a test of liver involvement in CF. Serum concentration of CA 19-9, liver enzymes, bile acids, and total amylase was determined in 107 CF patients (49 with and 58 without liver disease) and 56 healthy subjects. Serum CA 19-9 concentration was significantly higher in CF patients (67 U/ml, 95% Cl 53.5-80.5 U/ml) than in controls (11.8 U/ml, 95% Cl 2.5-44 U/ml; p <0.001) and in CF patients with liver disease (92.3 U/ml, 95% Cl 75-109.5 U/ml) compared to CF patients without liver disease (46.6 U/ml, 95% Cl 27.8-65.4 U/ml; p <0.001). In CF patients, stepwise logistic regression analysis identified alanine aminotransferase, γ-glutamyltranspeptidase, amylase, and CA 19-9 as the most useful predictors of liver disease (p <0.0001). Receiver-operating characteristic (ROC) curve analysis revealed γ-glutamyltranspeptidase and CA 19-9 as the best tests for identification of liver disease in CF patients; at a CA 19-9 cut-off arbitrarily fixed at 73 U/ml, positive and negative predictive value was 70% and 78%, respectively (sensitivity 57%, specificity 81%). To increase sensitivity to 94%, the cut-off had to be fixed at 31 U/ml, which corresponds to a specificity of only 36.2% (predictive value 33%). Our study indicates that measurement of the serum CA 19-9 concentration alone cannot be proposed as a reliable test of early hepatic involvement in CF.

KW - CA 19-9

KW - Cystic fibrosis

KW - Liver disease

UR - http://www.scopus.com/inward/record.url?scp=0037260297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037260297&partnerID=8YFLogxK

U2 - 10.1515/CCLM.2003.050

DO - 10.1515/CCLM.2003.050

M3 - Article

C2 - 12705340

AN - SCOPUS:0037260297

VL - 41

SP - 311

EP - 316

JO - Clinical Chemistry and Laboratory Medicine

JF - Clinical Chemistry and Laboratory Medicine

SN - 1434-6621

IS - 3

ER -